Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons

Neurology

Volumn 75, Issue 10, 2010, Pages 864-873

  Wright, E J ^a,b,c   Grund, B ^d   Robertson, K ^e   Brew, B J ^f,g   Roediger, M ^d   Bain, M P ^f   Drummond, F ^h   Vjecha, M J ⁱ   Hoy, J ^a,c   Miller, C ^d   Penalva De Oliveira, A C ^j   Pumpradit, W ^k   Shlay, J C ^l   El Sadr, W ^m   Price, R W ⁿ  

^a ALFRED HOSPITAL   (Australia)

^b BURNET INSTITUTE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f ST VINCENT S HOSPITAL   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^k THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^l DENVER PUBLIC HEALTH   (United States)

^m Columbia University ^*  (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; AUSTRALIA; BRAZIL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; COGNITION; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; DEMOGRAPHY; EDUCATION; FEMALE; GENDER; HEART INFARCTION; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RACE; THAILAND; VIRUS LOAD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK FACTOR; VIROLOGY;

ADULT; AUSTRALIA; BRAZIL; CARDIOVASCULAR DISEASES; COGNITION; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NORTH AMERICA; REGRESSION ANALYSIS; RISK FACTORS; THAILAND;

EID: 77957059542     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181f11bd8     Document Type: Article

References (40)

1. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors: Multicenter AIDS Cohort Study. Neurology 1993;43:2245-2252.
2. Bhaskaran K, Mussini C, Antinori A, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active anti-retroviral therapy. Ann Neurol 2008;63:213-221.
3. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4 + count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296.
4. Anstey KJ, von Sanden C, Salim A, O'Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol 2007;166:367-378.
5. Hayden KM, Zandi PP, Lyketsos CG, et al. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord 2006;20:93-100.
6. Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geri-atr Psychiatry 2008;16:343-354.
7. Silbert BS, Scott DA, Evered LA, Lewis MS, Maruff PT. Preexisting cognitive impairment in patients scheduled for elective coronary artery bypass graft surgery. Anesth Analg 2007;104:1023-1028.
8. Newman MF, Kirchner JL, Phillips-Bute B, et al. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med 2001;344:395-402.
9. Valcour VG, Shikuma CM, Shiramizu BT, et al. Diabetes, insulin resistance, and dementia among HIV-1-infected patients. J Acquir Immune Defic Syndr 2005;38:31-36.
10. Becker JT, Kingsley L, Mullen J, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology 2009;73:1292-1299.
11. Klove H. Clinical neuropsychology. Med Clin North Am 1963;47:1647-1658.
12. D'Elia LF, Satz P, Uchiyama CL, White T. Color Trails Test: Professional Manual. Odessa, FL: Psychological Assessment Resources; 1996.
13. Robertson KR, Parsons TD, Sidtis JJ, et al. Timed Gait test: normative data for the assessment of the AIDS dementia complex. J Clin Exp Neuropsychol 2006;28:1053-1064.
14. Reitan RM. Manual for Administration of Neuropsycho-logical Test Batteries for Adults and Children. Indianapolis: Reitan RM; 1969.
15. Wright E, Brew B, Arayawichanont A, et al. Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology 2008;71:50-56.
16. Price RW, Yiannoutsos CT, Clifford DB, et al. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS 1999;13:1677-1685.
17. ® Software Portfolio 2006. Available at: www3.parinc.com. Accessed March 30 2009.
18. Heaton RK, Miller SW, Taylor JJ, Grant I. Revised comprehensive norms for an expanded Halstead-Reitan battery: demographically adjusted neuropsychological norms for African Americans and Caucasian adults. Lutz, FL: PAR Psychological Assessment Resources, Inc.; 2004.
19. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69:1789-1799.
20. Radloff L. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
21. Van Voorhees BW, Fogel J, Houston TK, Cooper LA, Wang NY, Ford DE. Beliefs and attitudes associated with the intention to not accept the diagnosis of depression among young adults. Ann Fam Med 2005;3:38-46.
22. Perczek R, Carver CS, Price AA, Pozo-Kaderman C. Coping, mood, and aspects of personality in Spanish translation and evidence of convergence with English versions. J Pers Assess 2000;74:63-87.
23. Fleck MP, Lima AF, Louzada S, et al. [Association of depressive symptoms and social functioning in primary care service, Brazil.] Rev Saude Publica 2002;36:431-438
24. Center for Epidemiologic Studies-Depression Scale (CES-D). Available at: http://www.dmh.go.th/test/cesd/cesd/. Accessed July 30, 2010.
25. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121: 293-298.
26. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65:65-70.
27. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007;30:113-119. (Pubitemid 46052508)
28. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005;19:1375-1383
29. SMART/INSIGHT and D:A:D Study Groups. Use of nu-cleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22: F17-F24.
30. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001;322:1447-1451.
31. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 2009;66:300-305.
32. Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: The Rotterdam Study. Arch Neurol 2004;61:668-672.
33. Sattar N, Murray HM, Welsh P, et al. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Med 2009;6: e1000099.
34. Kowalska I, Straczkowski M, Nikolajuk A, et al. Insulin resistance, serum adiponectin, and proinflammatory markers in young subjects with the metabolic syndrome. Metabolism 2008;57:1539-1544.
35. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5:e203.
36. Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med 2009;17:118-123.
37. Guaraldi G, Zona S, Alexopoulos N, et al. Coronary aging in HIV-infected patients. Clin Infect Dis 2009;49:1756-1762.
38. Tisch S, Brew B. Parkinsonism in HIV-infected patients on highly active antiretroviral therapy. Neurology 2009; 73:401-403.
39. Manly JJ, Echemendia RJ. Race-specific norms: using the model of hypertension to understand issues of race, culture, and education in neuropsychology. Arch Clin Neuro-psychol 2007;22:319-325.
40. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol 2002;1:426-436.